Table 1.
Patient and tumor characteristics
| Clinicopathological Features | Patients n (%) | Clinicopathological Features | Patients n (%) |
| Menopausal status | T | ||
| Postmenopausal | 15 (25) | TIS | 3 (5) |
| Premenopausal | 39 (66) | pTx | 1 (2) |
| Unknown | 5 (9) | pT1 | 19 (33) |
| Histotype | pT2 | 22 (37) | |
| Ductal invasive | 45 (76) | pT3 | 2 (3) |
| Lobular invasive | 4 (7) | pT4 | 12 (20) |
| Intraductal | 3 (5) | Diameter (mm) | |
| Inflammatory | 4 (7) | ≤ 10 mm | 9 (15) |
| Other | 3 (5) | > 10 mm | 42 (71) |
| Grading | Unknown | 8 (14) | |
| G1 | 7 (12) | ||
| G2 | 18 (31) | N | |
| G3 | 26 (44) | pN1-3 | 20 (34) |
| Unknown | 8 (13) | pN4-10 | 9 (15) |
| Ki-67 | pN > 10 | 4 (7) | |
| 0–15% | 33 (56) | Negative | 19 (32) |
| 16–25% | 9 (15) | Unknown | 7 (12) |
| 26–100% | 14 (24) | HER-2 | |
| Unknown | 3 (5) | Positive | 31 (53) |
| ER/PgR | Negative | 28 (47) | |
| ER+/PgR+ | 38 (64) | ||
| ER-/PgR- | 12 (20) | LVI | |
| ER+/PgR- | 7 (12) | Positive | 27 (46) |
| ER-/PgR+ | 1 (2) | Negative | 24 (41) |
| Unknown | 1 (2) | Unknown | 8 (13) |
G, differentiation grade; G1-3, low, moderate or intermediate, high grade. ER, estrogen receptor alpha; PgR, progesterone receptor; T, tumor size; pT1, 0–2 cm; pT2, 2–5 cm; pT3, > 5 cm; pT4, ulcerated or attached; Tis, carcinoma in situ; pTX, primary tumor of unknown pT; N, node status; LVI, lymphovascular invasion; n, number of cases.